This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,000.00 to Mayo Clinic to conduct research aimed at enhancing the effectiveness of immune checkpoint blockade (ICB) immunotherapy for renal cell carcinoma (RCC). The project seeks to demonstrate that disrupting the ubiquitination or phosphorylation of the RIPK1 protein in RCC tumor cells can increase their susceptibility to killing by T cells in a TNF-dependent manner, thereby improving the response to ICB. Mayo Clinic will use its RAG and RENCA RCC cell line models to generate experimental evidence supporting this approach. The award period runs from September 19, 2023 through August 31, 2025.
Generated 7/16/24, 10:07 AM